MONTRÉAL, March 31, 2025 – Health Canada has granted marketing approval to Altuviiio (efanesoctocog alfa) for the treatment of hemophilia A in children, adolescents and...
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...
MONTREAL, February 25, 2025 – On February 20, Pfizer announced that it was stopping development of its hemophilia B gene therapy, Beqvez. It cited “soft...
CLICK HERE to access the 2025 ISSUE ONE of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
In June and July 2024, the Canadian Hemophilia Society conducted an online survey regarding the lived experience of people with hemophilia A and their caregivers....